『新加坡國際發明展』WorldInvent Singapore (WoSG) 2025，由新加坡Innovation Design & Entrepreneurship Association主辦專注於創新的展覽。

陽明交通大學林東毅教授率團隊以 【標靶 PD-L1 降解：可食用真菌蛋白GMI的腫瘤抑制策略】之研究成果，再次拿下國際發明展。團隊表示：透過阻斷PD-1/PD-L1啟動的癌症免疫治療是現代癌症免疫治療的新穎策略。雖然臨床上阻斷 PD-1/PD-L1 結合的單株抗體已顯示出良好益處，但直接下調癌細胞的PD-L1表現策略可能會進一步增強T細胞介導的腫瘤清除率。本作品展示可食用性真菌蛋白GMI透過促進 GSK3β 依賴性蛋白酶體降解顯著降低癌細胞中的PD-L1表現量。在小鼠模型中，GMI顯著抑制腫瘤生長並降低腫瘤組織中PD-L1表現。此外，GMI更能夠增強T細胞對癌細胞的毒殺能力，展現其作為具抗癌潛力之功能性食品。

Inhibition of the PD-1/PD-L1 immune checkpoint is a cornerstone of modern cancer immunotherapy. While monoclonal antibodies that block PD-1/PD-L1 binding have shown clinical benefit, strategies that directly downregulate PD-L1 expression may further enhance T-cell–mediated tumor clearance. Here, we show that GMI, an edible fungal immunomodulatory protein, markedly reduces PD-L1 levels in cancer cells by promoting GSK3β-dependent proteasomal degradation. In murine tumor models, systemic administration of GMI significantly suppressed tumor growth and decreased PD-L1 expression within the tumor lesions. In vitro assays further demonstrated that GMI enhances cytotoxic T-cell activity against cancer targets. Together, this invention highlights GMI as a promising functional-food–derived adjuvant capable of amplifying anti-tumor immune responses through direct modulation of PD-L1.

影片轉載自 TLlab